Oramorph (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Oramorph, is an opioid analgesic presented as a strength/form for oral use. It is used to treat moderate to severe pain in adult patients when other analgesics are insufficient. GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oramorph is an opioid analgesic that acts on the central nervous system to manage pain.

- Acute postoperative pain: provides rapid relief of pain following surgery. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Severe chronic pain: used when other analgesics fail to control chronic severe pain.

Adverse reactions to morphine may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Constipation - Drowsiness - Dry mouth - Sweating - Itching

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Bradycardia - Convulsions - Allergic reactions including anaphylaxis - Dependence and withdrawal syndrome.

When prescribing Oramorph, clinicians should consider several safety measures.

- Assess pain severity and opioid tolerance: ensure appropriate indication. - Evaluate respiratory function: monitor for depression, especially after dose changes. - Review patient history for substance abuse: risk of dependence. - Adjust dose in renal or hepatic impairment: use lower initial doses. - Avoid concurrent use with other central nervous system depressants. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Oramorph may interact with a range of medications that affect the central nervous system or opioid metabolism.

Major Interactions (​​​​​​​  ) : -  C  ​              ​    ​                         ​       ​      ​ ​       …  …  …  …  …  …  …  …  …  …  …  …  ... …  … …  ...  …  …  … … … … … … … … … … … …  t  … 

t  t  t     \